DeepMed Research

Traws Pharma, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 17

Market Cap: -

Website: http://www.trawspharma.com

Clinical Trials

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Drug: oral rigosertib
Drug: Azacitidine

First Posted Date: 2013-08-21

Last Posted Date: 2021-06-16

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 45

Registration Number: NCT01926587

Locations: 🇺🇸
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States

and more 10 locations

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Oral rigosertib

First Posted Date: 2013-07-22

Last Posted Date: 2021-06-16

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 45

Registration Number: NCT01904682

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Anschutz Cancer Pavilion University of Colorado, Aurora, Colorado, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 11 locations

Oral Rigosertib for Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Cervical Squamous Cell Carcinoma
Skin Squamous Cell Carcinoma
Penile Squamous Cell Carcinoma
Lung Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Anal Squamous Cell Carcinoma

Interventions: Drug: rigosertib

First Posted Date: 2013-03-08

Last Posted Date: 2017-06-26

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 64

Registration Number: NCT01807546

Locations: 🇺🇸
Blue Ridge Cancer Care, Salem, Virginia, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States

and more 10 locations

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Trisomy 8
MDS
Myelodysplastic Syndrome

Interventions: Drug: rigosertib

First Posted Date: 2012-04-25

Last Posted Date: 2017-06-26

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 82

Registration Number: NCT01584531

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 1 locations

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer
Cancer
Solid Tumors
Neoplasms

First Posted Date: 2012-02-24

Last Posted Date: 2017-06-23

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 42

Registration Number: NCT01538563

Locations: 🇺🇸
Albert Einstein Cancer Center, The Bronx, New York, United States

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer
Solid Tumors
Cancer
Neoplasms

First Posted Date: 2012-02-24

Last Posted Date: 2017-06-23

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 29

Registration Number: NCT01538537

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: ON 01910.Na
Drug: Gemcitabine

First Posted Date: 2011-05-26

Last Posted Date: 2016-08-04

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 160

Registration Number: NCT01360853

Locations: 🇺🇸
Desert Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
Premiere Oncology, Santa Monica, California, United States

and more 43 locations

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
MDS
RAEB
Chronic Myelomonocytic Leukemia

Interventions: Drug: ON 01910.Na

First Posted Date: 2010-11-16

Last Posted Date: 2020-06-30

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 299

Registration Number: NCT01241500

Locations: 🇺🇸
Edward H. Kaplan MD & Associates, Skokie, Illinois, United States
🇪🇸
Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸
Hospital Universitario La Paz, Madrid, Spain

and more 84 locations

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Myeloproliferative Disease
Acute Myelocytic Leukemia

Interventions: Drug: rigosertib

First Posted Date: 2010-07-22

Last Posted Date: 2017-06-26

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 30

Registration Number: NCT01167166

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: rigosertib

First Posted Date: 2010-07-22

Last Posted Date: 2017-06-23

Lead Sponsor: Traws Pharma, Inc.

Target Recruit Count: 68

Registration Number: NCT01168011

Locations: 🇺🇸
University of Colorado at Denver Health and Sciences, Denver, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy